The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Early Phase 1

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma
Brain Metastases

Interventions: Procedure: Magnetic Resonance Imaging (MRI)
Procedure: Positron Emission Tomography (PET)
Drug: 18F-fluoromisonidazole

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-18

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 48

Registration Number: NCT05996432

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients with Head and Neck Cancer

Phase 1

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Panitumumab-IRDye800
Other: Indium In 111 Panitumumab
Procedure: Single Photon Emission Computed Tomography
Procedure: Computed Tomography
Procedure: Resection
Procedure: Fluorescence Imaging

First Posted Date: 2023-07-14

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 40

Registration Number: NCT05945875

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer
Anatomic Stage II Breast Cancer
Anatomic Stage III Breast Cancer
Invasive Breast Lobular Carcinoma

Interventions: Procedure: Endocrine Therapy
Procedure: Biopsy of breast
Drug: Neratinib
Procedure: Biospecimen Collection
Procedure: Mammogram
Procedure: Magnetic Resonance Imaging
Procedure: Breast Surgery
Procedure: Ultrasound

First Posted Date: 2023-06-26

Last Posted Date: 2024-11-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT05919108

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Emory University/ Winship Cancer Institute, Atlanta, Georgia, United States

and more 2 locations

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Phase 1

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Biological: Panitumumab
Other: Indium In 111 Panitumumab
Procedure: Single Photon Emission Computed Tomography
Procedure: Computed Tomography
Procedure: Surgical Procedure
Other: Imaging agent
Procedure: Intraoperative Imaging
Procedure: Near Infrared Imaging
Procedure: Electrocardiography
Procedure: Biospecimen Collection

First Posted Date: 2023-06-13

Last Posted Date: 2024-12-13

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT05901545

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Phase 2

Suspended

Conditions: Metastatic Triple-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Sacituzumab Govitecan

First Posted Date: 2023-03-15

Last Posted Date: 2024-03-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 120

Registration Number: NCT05770531

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Phase 2

Suspended

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8
Refractory Melanoma
Metastatic Melanoma
Unresectable Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8

Interventions: Drug: Rigosertib
Biological: Pembrolizumab
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Procedure: Biopsy

First Posted Date: 2023-03-10

Last Posted Date: 2024-10-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 29

Registration Number: NCT05764395

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1

Recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage III Lung Cancer

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Biological: Pembrolizumab
Drug: Nab-paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Biological: Atezolizumab
Radiation: Radiation Therapy
Other: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan
Biological: Cemiplimab
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2022-08-15

Last Posted Date: 2024-10-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT05501665

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Phase 2

Recruiting

Conditions: Advanced Clear Cell Renal Cell Carcinoma
Metastatic Clear Cell Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8

Interventions: Biological: Ipilimumab
Drug: Cabozantinib
Biological: Nivolumab

First Posted Date: 2022-05-05

Last Posted Date: 2024-07-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 54

Registration Number: NCT05361720

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States

and more 3 locations

Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting

Not Applicable

Active, not recruiting

Conditions: Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma

Interventions: Procedure: Telemedicine Visit
Procedure: Vital sign measurements
Procedure: Out-Patient Clinic Visit
Procedure: Blood pressure and pulse oximeter

First Posted Date: 2021-11-05

Last Posted Date: 2024-03-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 25

Registration Number: NCT05108805

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer

Completed

Conditions: Renal Cell Carcinoma

Interventions: Other: Blood collection
Other: Urine collection

First Posted Date: 2021-05-12

Last Posted Date: 2024-10-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 180

Registration Number: NCT04883827

Locations: 🇺🇸
Tennessee Valley Health Care System, Nashville, Tennessee, United States
🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy